[ET Net News Agency, 16 January 2020] Morgan Stanley lowered its target price for 3SBio
Inc (01530) to HK$14.5 from HK$16 and maintained its "overweight" rating.
The research house projected sales growth of 19%, 19%, and 16% in 2019, 2020, and 2021,
respectively. It cut Yisaipu sales forecasts by 3%, 7%, and 13% for 2019-21, and more in
outer years, by 18-30%, to account for increasing competition after Humira and other
competing products' inclusion into 2019 NDRL (National Drug Reimbursement List), as well
as the recent approval of Humira biosimilars.
Morgan forecast 3SBio's net income growth of 22%, 20%, and 19% for 2019, 2020, and 2021,
slightly outpacing top-line growth on operating leverage. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01530 3SBIO
Nominal 
5.560 -0.100 (-1.767%) Research Report
16/01/2020 10:13
{I-bank focus}Morgan lowers 3SBio Inc (01530) to HK$14.5
| Remark: | Real time quote last updated: 19/04/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |